Gairik Sachdeva

Gairik Sachdeva is a seasoned business development and corporate strategy professional specializing in the biotechnology sector with a strong background in Strategy, Competitive Intelligence, Business Development, Financial Modeling, and Corporate Planning.

He holds a Doctor of Philosophy (PhD) in Bioengineering and Synthetic Biology from Harvard University, showcasing a blend of business acumen and scientific expertise.

With educational achievements including a Master of Liberal Arts (ALM) from Harvard Extension School, a Certificate from Harvard Business School Online, and a Bachelor of Technology (B.Tech.) from IIT Madras, Gairik has a well-rounded academic foundation.

In his professional journey, Gairik has held key positions such as Senior Director and Former Director of Business Development at Arbor Biotechnologies, where he contributed significantly to the company's growth and strategic goals.

Prior to his tenure at Arbor Biotechnologies, he served as Senior Manager of Corporate Strategy and Market Insights at Karyopharm Therapeutics Inc., showcasing his versatility in different domains of the biotechnology industry.

He has also brought his expertise to consultancy roles, having worked at Trinity Partners and Clarion - A Life Sciences Consultancy in various capacities, including as a Consultant, Senior Associate, and Project Manager, illustrating his proficiency in managing and executing strategic projects.

Furthermore, Gairik Sachdeva has leveraged his knowledge as a Teaching Fellow at Harvard University, sharing insights on Energy Perspectives, Problems, and Prospects, underlining his commitment to knowledge sharing and academic pursuits.

His industrious nature is evident from his summer research position at the California Institute of Technology, where he actively engaged in scientific exploration and research initiatives.

Overall, Gairik Sachdeva's extensive academic background, coupled with his diverse professional experiences in business development, corporate strategy, and the biotechnology industry, position him as a valuable asset and a thought leader in his field.